Publications, Pharmaceutical

Aptar Pharma Q&A on trends and challenges in nasal drug delivery

Nasal drug delivery is currently the focus of considerable drug development activity.

This Q&A takes a detailed look at the nasal drug delivery landscape and the potential of this route for the delivery of vaccines and therapeutics for COVID-19, for nose-to-brain drug delivery and for improving the accessibility of emergency medications. Key challenges associated with the development of nasal drug products are outlined along with factors impacting device design and selection.
The regulatory landscape is also considered. Barriers to the development of nasal drug delivery products are examined but it is concluded that the route has a bright future with considerable potential to address currently unmet therapeutic needs.

Download the Q&A
Author(s): Dr Julie D. Suman
21 Apr 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

26 Feb 2024

Intranasal Delivery of Monoclonal Antibodies via Dry Powder

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
2 Feb 2024

Systemic Nasal Drug Delivery for CNS Diseases and Beyond

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
30 Jan 2024

Nanoparticle Formulation Strategies for Intranasal Drug Delivery

Publications, Pharmaceutical, Market Insights, Product Solutions, Device Innovations

Read More
3 Jan 2024

Feasibility of Intranasal Delivery of Thin-Film Freeze-Dried Monoclonal Antibodies

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
1 2 3 4 5 6 27

Request Access

Close

Requesting access to Aptar Pharma Q&A on trends and challenges in nasal drug delivery.

  • This field is for validation purposes and should be left unchanged.
Back To Top